NW Bio To Webcast, Live, at VirtualInvestorConferences.com On May 7

News provided by

May 06, 2015, 08:00 ET

Company invites individual and institutional investors as well as advisors to attend real-time VirtualInvestorConferences.com

BETHESDA, Md., May 6, 2015 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that Linda Powers, NW Bio CEO, will present a live overview of the Company's DCVax cancer vaccine platform for solid tumor cancers and the Company's multiple clinical programs at VirtualInvestorConferences.com on May 7, 2015.

DATE:	Thursday, May 7, 2015
TIME:	12:15 PM EDT
LINK:	http://VirtualInvestorConferences.com click on the red "register/watch event now"

It is recommended that investors pre-register to save time and receive event updates.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe. The Company has a broad platform technology for DCVax dendritic cell-based vaccines. The Company's lead program is a 348-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease." The Company is under way with a 60-patient Phase I/II trial with DCVax-Direct for all inoperable solid tumors cancers. It has completed enrollment in the Phase I portion of the trial, and is in preparation for two Phase II trials. The Company previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer. The Company conducted a Phase I/II trial with DCVax for metastatic ovarian cancer together with the University of Pennsylvania. In Germany, the Company has also received approval of a 5-year Hospital Exemption for the treatment of all gliomas (brain cancer) patients outside the clinical trial.

About VirtualInvestorConferences.com

VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PR Newswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future events or developments relating to existing clinical trials and future clinical trials, and future business activities or events, opportunities or prospects, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "design," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks related to the Company's ongoing ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, uncertainties about the clinical trials process, uncertainties about the timely performance of third parties, uncertainties related to regulatory risks or decisions, risks related to whether the Company's products will demonstrate safety and efficacy, risks related to the Company's and Cognate's abilities to meet all manufacturing related requirements and to carry out the intended manufacturing expansions contemplated in the Cognate Agreements, risks related to the Company's ability to carry out the Hospital Exemption program and risks related to possible reimbursement and pricing. Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

Logo - http://photos.prnewswire.com/prnh/20150506/214161LOGO

SOURCE Northwest Biotherapeutics